...ReproCell acquired the induced pluripotent stem cell (iPSC) reagents and services business of Stemgent Inc. , now...

...Stemgent for $9 million in cash (see BioCentury, July 23). BioSeek plc (LSE:ATD), Royston, U.K. Stemgent Inc....

...In June, Stemgent said it will acquire Asterand's non-BioSeek Tissue Based Solutions business for $9 million...
...Feb. 22, 2010; Oct. 31, 2011 & May 7, 2012). Asterand plc (LSE:ATD), Royston, U.K. Stemgent Inc....

...patient-specific samples," said Matthew Singer, manager of scientific development at iPS cell and reagent company Stemgent Inc....
...Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Stanford University, Stanford, Calif. StemCells Inc. (NASDAQ:STEM), Palo Alto, Calif. Stemgent Inc....

...Miltenyi received exclusive rights to commercialize Stemgent's existing stem cell product portfolio outside the U.S. Stemgent...
...will join Stemgent's board. Financial terms were undisclosed. Miltenyi Biotec GmbH , Bergisch Gladbach, Germany Stemgent Inc....

...therapy Date completed: 3/3/10 Type: Venture financing Raised: £3 million ($4.5 million) Investor: Stemgent Inc. Note: Stemgent...

...cells for research or therapeutic use . In April, Fate and reagent and tool company Stemgent Inc....

...Fate and Stemgent established the Catalyst program to provide induced pluripotent stem (iPS) cell technology to...
...Fate's iPS technology with Stemgent's reagents and tools. Fate Therapeutics Inc. , La Jolla, Calif. Stemgent Inc....

...LSE:ATD), Royston, U.K. Business: Functional genomics, ADMET, Supply/Service Appointed: Ian Ratcliffe, president and CEO of Stemgent Inc. WIR...